share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Paggiarino Dario A.

SEC announcement ·  Apr 3 05:30
Summary by Futu AI
On March 30, 2024, Dario A. Paggiarino, Chief Medical Officer of EyePoint Pharmaceuticals, completed a series of transactions involving the company's common stock. Paggiarino acquired a total of 50,404 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,546 shares at a price of $20.67 per share, primarily to cover exercise prices or tax liabilities associated with the transactions. Following these transactions, Paggiarino's direct holdings in EyePoint Pharmaceuticals amounted to 67,080 shares. The total market value of the disposed shares was approximately $528,035.82.
On March 30, 2024, Dario A. Paggiarino, Chief Medical Officer of EyePoint Pharmaceuticals, completed a series of transactions involving the company's common stock. Paggiarino acquired a total of 50,404 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,546 shares at a price of $20.67 per share, primarily to cover exercise prices or tax liabilities associated with the transactions. Following these transactions, Paggiarino's direct holdings in EyePoint Pharmaceuticals amounted to 67,080 shares. The total market value of the disposed shares was approximately $528,035.82.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.